dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· July 20, 2026

Are ServiceNow’s New AI Integrations Quietly Redefining Its Platform Moat for Investors in NOW?

View original at finance.yahoo.com
Are ServiceNow’s New AI Integrations Quietly Redefining Its Platform Moat for Investors in NOW?…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ServiceNow's forecasts yield a $141.86 fair value, a 35% upside to its current price.

    60% confidence
  • The biggest risk to ServiceNow remains execution in AI and new workflows, where rapid change and strong competition could pressure both growth and margins.

    60% confidence
  • ServiceNow's narrative projects $23.6 billion revenue and $4.0 billion earnings by 2029.

    60% confidence
  • To own ServiceNow today, investors need to believe its AI Platform becomes core plumbing for enterprise workflows, supporting durable subscription growth despite sharp share price declines and AI disruption worries.

    60% confidence
  • The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it.

    60% confidence
  • Reaching the 2029 projection requires 19.1% yearly revenue growth and a $2.2 billion earnings increase from $1.8 billion.

    60% confidence

Data points we hold from this source

ServiceNow · upside potential35 percent
ServiceNow · fair value141.86 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Are ServiceNow’s New AI Integrations Quietly Redefining Its Platform Moat for Investors in NOW?: Source | Via News | fr.via.news